Although afatinib is the standard drug for the treatment of lung squamous cell carcinoma (SCC) with EGFR overexpression, attempts have been made to use this irreversible blocker for other EGFR expressing tumors. The gene discussed is EGFR; the disease is squamous cell lung carcinoma.